



## Editorial Article

**FAILURE OF DRUG MANUFACTURING PROJECT; WORTH OF APPROXIMATELY RS. 0.8 BILLION, AFTER 18 YEARS OF ITS DEPLOYMENT; BECAUSE OF CORRUPTION OF DEAN PHARMACY AND PARTNER OF THE FIRM M/S UNIVERSITY OF SARGODHA PHARMACEUTICAL LABORATORIES.**

## Taha Nazir

1. Acting President – Pakistan Pharmacist Association (PPA).  
<http://pakistanpharmacistsassociation.com>
2. Ex-President - Pharmacist Federation (Pakistan). <http://pharmacistfed.wordpress.com>
3. Editor-in-Chief, Pharmaceutical Review. ISSN 2220-5187 |  
<http://pharmaceuticalsreview.com>

## History:

Received: April 3, 2022  
Revised: April 21, 2022  
Accepted: April 26, 2022  
Published: April 27, 2022  
Collection year: 2022  
Status: Published

## Identifiers and Pagination:

Year: 2022  
Volume: 13  
First Page: 9  
Last Page: 12  
Publisher ID: 22205187. 27042022  
doi:<http://dx.doi.org/10.52182/22205187.27042022>

Thomson Reuters - ID N-5730-2015  
ORCID ID - [orcid.org/0000-0002-5308-6798](http://orcid.org/0000-0002-5308-6798)  
[ResearchGate](https://www.researchgate.net) | [Scopus](https://scopus.com) | [LinkedIn](https://www.linkedin.com)

**Correspondence:** Taha Nazir PhD (Microbiology) Editor in Chief, Pharmaceutical Review  
ISSN: 2220-5187, <http://pharmaceuticalsreview.com>, [taha@pharmaceuticalsreview.com](mailto:taha@pharmaceuticalsreview.com)

## Correspondence:

**Taha Nazir** Ph.D. Acting President -  
Pakistan Pharmacist Association  
(PPA). +92 321 222 0885  
[tahanazir@yahoo.com](mailto:tahanazir@yahoo.com)

**Running title:** Healthcare system and pharmaceutical patient care.

**Conflict of interest:** Author accepts all potential conflict of interest.

**Ethics approval and consent to participate:** No ethical approval needed for this work.

**Consent for publication:** Author is agreed to submit this article for publication in  
Pharmaceutical Review - ISSN 2220-5187.

**Availability of data and materials:** The data collected, analyzed and incorporated in this  
study is included in this article.

**doi:** <http://dx.doi.org/10.52182/22205187.27042022>

## Citation:

Taha Nazir. Failure of drug  
manufacturing project; worth of  
approximately Rs. 0.8 billion, after  
18 years of its deployment; because  
of corruption of Dean Pharmacy  
and partner of the firm m/s  
University of Sargodha  
Pharmaceutical Laboratories.  
Pharm Rev. Vol. 13. 2022. P. 9-12

The pharmaceutical preparation on industrial scale is a unique business model to produce the lifesaving drugs. Medicines produced through a series of operations in an organized scientific pattern. Tablet, syrup, injection, ampules, cream, ointments, suppository, pessaries, and suspension are manufactured by potential parts of the processes including milling, drying, mixing, granulation, heating, coating and pressing. The active ingredient or drug is processed primarily to produce the final dosage form by a secondary processing, conversion of the active drugs into products suitable for administration or usage in actual clinical practice.

So, a drug manufacturing project was deployed in University of Sargodha along with the start of undergraduate degree program of Pharm-D in 2005. Unluckily, the project of about Rs. 0.8 billion failed because of the corruption of Dean Pharmacy and partner of the firm M/s University of Sargodha Pharmaceutical Laboratories.

## Funding:

The authors received no direct  
funding for this research.

## Competing Interests:

The authors declare no competing  
interests

Additional information is available at  
the end of the article.

Therefore, an investigation and strict disciplinary action against this corruption is requested to **Umar Sarfaraz Cheema**, Governor of the Punjab, and Chancellor of the University of Sargodha, Lahore, under application No. 379/627 dated April 25, 2022. The case is filed to recover the damage from the responsible culprit.

Furthermore, in continuation of Higher Education Commission's letter No. 05-48/A&C(Affairs)/2016/7151 dated July 01, 2016, forward the matter to concerned university for comments; letters No.: 171/Pharm/ 2017 dated January 24, 2017 regarding "Explanation of Letter No. UOS/Pharm/4692 Dated 17.1.2017"; letter dated November 25, 2015 Diary No. UOS/Pharm/1998, VCD No. 16311 dated 26.11.2015 and letter No. nil, dated March 15, 2016 VCD submitted in the office of the Vice Chancellor, University of Sargodha, the author of this article is ambitious to continue the struggle against corruption. The Dean Pharmacy Prof. Dr. Sajid Bashir has played major role to purchase the substandard and used machinery for the University of Sargodha Pharmaceutical Laboratories. The equipment were purchased from a supplier located in Industrial Area, Saggian Bypass, Lahore under the purchase order numbers,

- 1 UOS/RC/11-412 dated 21.03.2011
- 2 UOS/RC/10-160 dated 25.05.2010
- 3 UOS/RC/11-616 dated 18.10.2011
- 4 UOS/RC/11-615 dated 18.10.2011 and
- 5 UOS/RC/11-624 dated 21.10.2011

Manufacturing license No. 000859/167 dated 12.06.2017 granted by Chairman Central Licensing Board, Government of Pakistan under the Drug Act 1976. Unluckily, the potential profitable and excellent drug manufacturing project of approximately Rs. 0.8 billion was failed because of the corruption of aforesaid officer. The granted license was then voluntarily surrendered by University of Sargodha under letter No. UOS/PIU/1666 dated November 19, 2018 and facility was shut down. So, a strict disciplinary action against the corruption of the Dean Pharmacy, University of Sargodha is requested.

M/s University of Sargodha Pharmaceutical Laboratories was granted license No. 000859 dated June 12, 2017 to manufacture the drugs by the way of formulation at the premises of University Road, Sargodha. The license permits the manufacture of drugs registered under the Drugs Act, 1976. The license, in addition to the conditions specified in the rules made under the Drugs Act 1976, be subject to the following conditions, namely:-

- i. The license will be in force for a period of five years from the date of issue unless earlier suspended or cancelled.
- ii. The license authorizes the sale by way of wholesale dealing and storage for sale by the licensee of the products manufactured under this license, subject to the conditions applicable to licenses for sale.
- iii. Names of the approved expert staff.

The license was issued with the signature of the then secretary and Chairman, Central

Licensing Board, Government of Pakistan, Islamabad, Pakistan.

Refer to the letter number UOS/PIU/1666 dated November 19, 2018 of University of Sargodha with the subject of “Cancellation of Drug Manufacturing License No. 000859 (formulation) of M/S University of Sargodha Pharmaceutical laboratories, Sargodha” and personal hearing letter dated February 19, 2019; Ministry of National Health Services, Regulations & Coordination, Drug Regulatory Authority of Pakistan, government of Pakistan has undertaken the matter. The case was placed before 269 meeting of Central Licensing Board held on February 26, 2019, The Central Licensing Board considered all facts and request of the University of Sargodha and decided to “**CANCELLED**” the license. A Lecturer of Faculty of Pharmacy, University of Sargodha, appeared before the Board and contended that due to change in management at the University decision has been taken to shut the facility and therefore request has been submitted for voluntarily cancellation of Drug Manufacturing License by way of formulation. It was further contended that University may be allowed to avail the facility for research purpose. The Board after hearing the representative of the University decided to cancel the Drug Manufacturing License No. 000859 by way of Formulation in the name of M/s University of Sargodha Pharmaceutical Laboratories, Sargodha under Section 41 of the Drugs Act, 1976 read with Rule 12 of the Drugs (Licensing, Registering and Advertising) Rules, 1976. The Board also decided to seek detailed proposal from the University for future utility of the facility”.

Thus, the said Manufacturing License was cancelled with immediate effect under the Drugs Act, 1976 and rules framed there under. Manufacturing of Drugs in the name of said license and at said Premises is prohibited and punishable offence under section 23 and 27 of the Drugs Act, 1976 and rules framed there under. University of Sargodha Pharmaceutical Laboratories was advised to submit detailed proposal for future utility of faculty at the earliest.

So, the facility was then used for research purpose after successful failure the project matured and become functional after a constant professional skilled working and utilization of huge public resources for a long time of about 18 years. There are already four undergraduate research laboratories along with a post-graduation Hi-Tech Lab with excellent research equipment’s and facilities. The project of approximately Rs. 0.8 billion is shut downed to veil and undercover the corruption of dean pharmacy, University of Sargodha; Partner of the University of Sargodha Pharmaceutical Laboratories. He is major player and mainly responsible of the failure of this amazing and innovative project.



© 2022 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions: You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits